Loading publications…
The last 5 uploaded publications
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
Christopher J. Sweeney, Andrew Martin, Martin R. Stockler, Stephen Begbie, Leanna Cheung, Kim N., Simon Chowdhury, Mark Frydenberg, Lisa G. Horvath, Anthony M. Joshua, Nicola Jane Lawrence, Gavin Marx, John McCaffrey, Ray McDermott, Margaret McJannett, Scott North, Francis Parnis, Wendy R. Parulekar, David Pook, M. Neil Reaume, Shahneen Sandhu, Alvin Tan, Thean Hsiang Tan, Alastair Thomson, Francisco Vera-Badillo, Scott Williams, Diana Winter, Sonia Yip, Alison Y. Zhang, Robert Zielinski, Ian D. Davis, Ehtesham Abdi, Suzanne Allan, Patricia Bastick, Stephen Begbie, Robert Blum, Karen Briscoe, Daniel Brungs, Sean Bydder, Bala Renuka Chittajallu, Michelle R. Cronk, Katharine Cuff, Ian D. Davis, Anthony Dowling, Mark Frydenberg, M. C. George, Lisa G. Horvath, Elizabeth Hovey, Anthony M. Joshua, Narayan Karanth, Ganessan Kichenadasse, Laurence E. Krieger, Gavin Marx, Maitham Mathlum, Louise Nott, Zulfiquer Otty, Francis Parnis, David Pook, Shahneen Sandhu, Sanjeev Sewak, Amanda Gwendolyn Stevanovic, Martin R. Stockler, Aneta Suder, Hsiang Tan, Javier Torres, Simon Troon, Craig Underhill, Andrew Weickhardt, Robert Zielinski, Tahir Abbas, Ghadeer Anan, Chris Booth, H. E. A. Campbell, Kim Chi, Joseph L. Chin, E. Chouinard, Bryan Donnelly, Darrel Drachenberg, Amir Faghih, Antonio Finelli, Sébastien J. Hotte, Krista Noonan, Scott North, Mohammad Rassouli, Neil Reaume, Ricardo Rendon, Fred Saad, Evgeny Sadikov, Éric Vigneault, Paweł Zalewski, John McCaffrey, Ray McDermott, Patrick G. Morris, Miriam O’Connor, Paul Donnellan, Dearbhaile M. O’Donnell, Joanne Edwards, Peter C.C. Fong, Alvin Tan, Simon Chowdhury (2023). Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. , 24(4), DOI: https://doi.org/10.1016/s1470-2045(23)00063-3.
Article62 days agoManagement of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)
Ana M. Aparicio, Andrew J. Armstrong, Diogo Assed Bastos, Gerhardt Attard, Karol Axcrona, Mouna Ayadi, Himisha Beltran, Anders Bjartell, Pierre Blanchard, María T. Bourlon, Alberto Briganti, Muhammad Bulbul, Consuelo Buttigliero, Orazio Caffo, Daniel Castellano, Elena Castro, Heather H. Cheng, Kim N., Caroline S. Clarke, Noel W. Clarke, Johann S. de Bono, Maria De Santis, Ignacio Durán, Eleni Efstathiou, Onyeanunam Ngozi Ekeke, Tamer I H El Nahas, Louise Emmett, Stefano Fanti, Omolara Fatiregun, Felix Y. Feng, Peter C.C. Fong, Valérie Fonteyne, Nicola Fossati, Daniel J. George, Martin Gleave, Gwénaëlle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Michael S. Hofman, Thomas A. Hope, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek‐Fossa, Robert J. Jones, Anthony M. Joshua, R. Kanesvaran, Daniel Keizman, Raja B. Khauli, Gero Kramer, Stacy Loeb, Brandon A. Mahal, Fernando Cotait Maluf, Joaquı́n Mateo, David Matheson, Mika Matikainen, Ray McDermott, Rana R. McKay, Niven Mehra, Axel S. Merseburger, Alicia K. Morgans, Michael J. Morris, Hind Mrabti, Deborah Mukherji, Silke Gillessen, Fabio Turco, Ian D. Davis, Jason A. Efstathiou, Karim Fizazi, Nicholas D. James, Neal D. Shore, Eric J. Small, Matthew R. Smith, Christopher J. Sweeney, Bertrand Tombal, Thomas Zilli, Neeraj Agarwal, Emmanuel S. Antonarakis, Declan G. Murphy, Vedang Murthy, Shingai B.A. Mutambirwa, Paul L. Nguyen, William Oh, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Chris Parker, Darren M.C. Poon, Colin C. Pritchard, Danny Rabah, Dana E. Rathkopf, Robert E. Reiter, Raphaële Renard‐Penna, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Shahneen Sandhu, Oliver A. Sartor, Edward M. Schaeffer, Howard I. Scher (2024). Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). , DOI: https://doi.org/10.1016/j.eururo.2024.09.017.
Article62 days agoTestosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
Christopher J. Sweeney, Andrew Martin, Martin R. Stockler, Stephen Begbie, Leanna Cheung, Kim N., Simon Chowdhury, Mark Frydenberg, Lisa G. Horvath, Anthony M. Joshua, Nicola Jane Lawrence, Gavin Marx, John McCaffrey, Ray McDermott, Margaret McJannett, Scott North, Francis Parnis, Wendy R. Parulekar, David Pook, M. Neil Reaume, Shahneen Sandhu, Alvin Tan, Thean Hsiang Tan, Alastair Thomson, Francisco Vera-Badillo, Scott Williams, Diana Winter, Sonia Yip, Alison Y. Zhang, Robert Zielinski, Ian D. Davis, Ehtesham Abdi, Suzanne Allan, Patricia Bastick, Stephen Begbie, Robert Blum, Karen Briscoe, Daniel Brungs, Sean Bydder, Bala Renuka Chittajallu, Michelle R. Cronk, Katharine Cuff, Ian D. Davis, Anthony Dowling, Mark Frydenberg, M. C. George, Lisa G. Horvath, Elizabeth Hovey, Anthony M. Joshua, Narayan Karanth, Ganessan Kichenadasse, Laurence E. Krieger, Gavin Marx, Maitham Mathlum, Louise Nott, Zulfiquer Otty, Francis Parnis, David Pook, Shahneen Sandhu, Sanjeev Sewak, Amanda Gwendolyn Stevanovic, Martin R. Stockler, Aneta Suder, Hsiang Tan, Javier Torres, Simon Troon, Craig Underhill, Andrew Weickhardt, Robert Zielinski, Tahir Abbas, Ghadeer Anan, Chris Booth, H. E. A. Campbell, Kim Chi, Joseph L. Chin, E. Chouinard, Bryan Donnelly, Darrel Drachenberg, Amir Faghih, Antonio Finelli, Sébastien J. Hotte, Krista Noonan, Scott North, Mohammad Rassouli, Neil Reaume, Ricardo Rendon, Fred Saad, Evgeny Sadikov, Éric Vigneault, Paweł Zalewski, John McCaffrey, Ray McDermott, Patrick G. Morris, Miriam O’Connor, Paul Donnellan, Dearbhaile M. O’Donnell, Joanne Edwards, Peter C.C. Fong, Alvin Tan, Simon Chowdhury (2023). Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. , 24(4), DOI: https://doi.org/10.1016/s1470-2045(23)00063-3.
Article62 days agoPoly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer
Shahneen Sandhu, Aurelius Omlin, Lucy Hylands, Susana Miranda, Louise J. Barber, Ruth Riisnaes, Alison Reid, Gerhardt Attard, L. Chen, Iwanka Kozarewa, Heidi Gevensleben, James Campbell, Kerry Fenwick, Ioannis Assiotis, David Olmos, Timothy A. Yap, Peter C.C. Fong, Nina Tunariu, Dow‐Mu Koh, L. Rhoda Molife, S.B. Kaye, Christopher J. Lord, Alan Ashworth, Johann S. de Bono (2013). Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. , 24(5), DOI: https://doi.org/10.1093/annonc/mdt074.
Letter62 days agoA first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors
Shahneen Sandhu, K. Papadopoulos, Peter C.C. Fong, Amita Patnaik, Christina Messiou, David Olmos, George Wang, Brenda Tromp, Thomas A. Puchalski, Frances R. Balkwill, Birge Berns, Shobha Seetharam, Johann S. de Bono, Anthony W. Tolcher (2013). A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. , 71(4), DOI: https://doi.org/10.1007/s00280-013-2099-8.
Article62 days ago